GLP-1 and SGLT2 drugs — could significantly reduce the risk of developing dementia in life, a large new study has found.

C an drugs like Ozempic slow down the development of cognitive diseases, such as dementia and Alzheimer’s? According to ...

It’s possible that they may play a role as a preventative measure in the future,” said Dr. Catriona Reddin told The Post.

Drugs originally developed to treat type 2 diabetes, particularly GLP-1 receptor agonists such as semaglutide (sold as ...

As the Trump administration makes cuts to federal health agencies, some Alzheimer's experts are worried about the impact on ...

Leqembi — sold through a partnership between Eisai Co. and Cambridge-based Biogen — is one of the first medications approved ...

A major new study finds that certain diabetes medications, including GLP-1 and SGLT2 inhibitors, may be linked to a reduced ...

Delve into how the biotech industry is pivoting from the amyloid hypothesis to find new Alzheimer's disease treatments.

Early-onset Alzheimer’s disease progresses more rapidly and often strikes people in the prime of their lives. A new treatment ...

Alzheimer's disease, the most common cause of dementia, is currently incurable. The current drugs available have very limited ...

In the first arrangement of its kind, Eli Lilly to connect patients through telemedicine to providers of Alzheimer’s drugs.

W ith two new treatments for Alzheimer’s disease approved in recent years, there’s growing hope for people at risk of the ...